WuXi XDC Included in MSCI China All Share Index
SHANGHAI, Aug. 8, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the MSCI China All Share Index, which underscores global capital markets' recognition of the company's sustained growth value and leadership in the bioconjugate CRDMO...
WCC Biomedical@NACDS Total Store Expo: Advancing Microneedle Drug Delivery With WINMAP™ Platform
TAIPEI, Aug. 8, 2025 /PRNewswire/ -- WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launch two new products. Chairman of Synmosa biopharma group, Peter Lin (Second from the left), and Chiarman...
CHICAGO RIVER SWIM APPROVED FOR HISTORIC RETURN THIS SEPTEMBER
First Organized Swim in Nearly a Century will Raise Funds for ALS Research and Youth Swimming Lessons WHAT: Open Water Swim in the Main Stem of the Chicago RiverWHEN: September 21, 2025 | 7:00AM – 10:00AMWEBSITE: ChicagoRiverSwim.org CHICAGO, Aug. 7, 2025 /PRNewswire/ -- The City of Chicago has officially approved the 2025 Chicago River...
LabConnect Partners with Kits4Life to Reduce Kit Waste and Advance Sustainable Clinical Trials
JOHNSON CITY, Tenn., Aug. 8, 2025 /PRNewswire/ -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an initiative of the MedSurplus Alliance. This collaboration reflects our broader ESG strategy and strengthens LabConnect's role as the world's...
Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion
SHANGHAI, Aug. 7, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led by Qiming Venture Partners. Further support came from existing investor TF Capital, and seven new investors, including including BioTrack Capital, 5Y Capital, New Day Fund, and Wider...
US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second program IND has been submitted to US FDA for clinical...
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines,...
Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
BRADENTON, Fla., Aug. 6, 2025 /PRNewswire/ -- Continuity Biosciences, a company pioneering next-generation combination product drug delivery, today announced the appointment of two highly distinguished leaders to its Board of Directors: Josephine M. Torrente, Director at Hyman, Phelps & McNamara, P.C., and Dr. Joseph M. DeSimone, serial entrepreneur and professor at Stanford...
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA),...
The U.S. FDA Granted Fast Track Designation to Dizal’s Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed...
